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Abstract
Background: Cytomegalovirus (CMV) is a prevalent herpesvirus with links to both stress and aging. This paper
describes and validates a minimally invasive method for assessing antibodies against CMV in finger stick whole
blood spot samples for use as an indirect marker of an aspect of cell-mediated immunity.
Results: Analysis of CMV in dried blood spot samples (DBS) was based on modifications of a commercially
available protocol for quantifying CMV antibodies in serum or plasma. The method was evaluated through analysis
of precision, reliability, linearity, and correlation between matched serum and DBS samples collected from
75 volunteers. Correlation between DBS and plasma values was linear and high (Pearson correlation R = .96),
and precision, reliability, and linearity of the DBS assay were within acceptable ranges.
Conclusions: The validity of a DBS assay for CMV antibodies will enable its inclusion in population-based surveys
and other studies collecting DBS samples in non-clinical settings, increasing scientific understanding of the
interaction of social and biological stress and immune function.
Background
Immune system decline is one of the hallmarks of aging.
Age-associated alterations in systemic immunity,
referred to as ‘immunosenescence’, are thought to con-
tribute to the increased incidence and severity of infec-
tious disease in older persons, as well as decreased
response to vaccination [1,2]. Increasing evidence sug-
gests that the persistent herpesvirus cytomegalovirus
(CMV) plays an important role in human immunosenes-
cence, meriting special attention in studies designed to
understand stress, immune function, and health [3].
This paper describes and validates a minimally invasive
method for assessing antibodies against CMV in dried
whole blood spot samples. The collection of dried blood
spots (DBS)-drops of whole blood on filter paper from a
single finger prick-has rece n t l yb e c o m eap o p u l a rm i n i -
mally invasive technique for collecting biomarkers in
population surveys [4]. Since most standard laboratory
protocols require serum or plasma, assay protocols must
be developed specifically for DBS and validated for accu-
racy, precision, reliability, and limits of detection. This
validation of a dried-blood spot assay for CMV antibo-
dies will facilitate its broad inclusion in population-
based surveys and other studies collecting biomarkers in
non-clinical settings, increasing scientific understanding
of the interaction of social and biological stress and
immune function.
The importance of cytomegalovirus (CMV) as a marker of
immune function and aging
CMV is a ubiquitous herpesvirus that is most often
asymptomatic and acquired early in life, with most
populations reaching over 70% seroprevalence for those
over age 60 [5,6]. Once acquired, CMV remains latent
in the host for life, with containment of the virus
becoming an immune system priority. Accumulating
evidence suggests that CMV may play a direct role in
immune system aging, and CMV infection has even
been called the “driving force” behind age-associated
alterations to the T cell immune system [3]. Higher
CMV antibody levels in conjunction with CMV DNA
shedding in urine indicating subclinical reactivation
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infected with CMV[7]. Aging populations experience
increased CMV specific CD8+ T-cell accumulation and
a reduction in naïve T cells, potentially reducing the
availability of CD8+ T-cell carrying receptors that are
specific for pathogens or foreign antigens other than
CMV[8]. This CMV-specific CD8+ T cell accumulation
may play a role in the decreased ability of the elderly to
resist new infections, though recent rodent evidence
suggests that the “immunological space” m a yb em o r e
flexible than previously believed[9]. Recent findings have
shown that latent CMV infection in the elderly is an
important component of a set of immunological para-
meters designated the “immunological risk pheno-
type”[3]. This set of immunological markers-including
latent CMV infection, high CD8 cells, low CD4 cell per-
centages, poor T-cell proliferation-is predictive of mor-
tality among healthy elderly individuals [3,10]. A large
fraction of the available adaptive immune resource is
focused on CMV, as high as 10-30% of all CD4 cells
and 50% of all CD8 cells in elderly individuals [11,12].
CMV IgG antibody titers have been found to increase
linearly with CMV viral load in leukocytes, suggesting
they are a good indicator of host immune response to
viral replication[13,14].
Increased anti-CMV IgG antibodies have been asso-
ciated with higher levels of the inflammatory cytokines
TNF-a and IL-6 along with reduced immune response
to influenza vaccination among both young and older
individuals [15]. CMV-specific CD8 T cells also have the
ability to produce IFN-g [16]. Thus, an accumulation of
CMV specific CD8 T cells may lead to an increase in
several circulating inflammatory cytokines in the elderly,
including TNF-a,I F N - g,a n dI L - 6 .A ni n c r e a s ei n
chronic peripheral cytokine concentration and reduced
repertoire of T cells is likely to influence pathophysiolo-
gical changes associated with chronic health conditions
and mortality. In epidemiological studies, CMV antibo-
dies have been linked to inflammatory processes, cardio-
vascular disease, frailty, cognitive decline, and mortality
[17-21].
Stress and Immune function
Adequate cell-mediated immunity is important for
maintaining persistent infe c t i o n ss u c ha sc y t o m e g a l o -
virus (CMV), Epstein-Barr virus (EBV) or herpes sim-
plex virus type 1 (HSV-1) in a latent state. Stress-related
down regulation of cellular immunity can allow a her-
pesvirus to reactivate, releasing viral antigens into circu-
lation. In turn, levels of antibodies to CMV, EBV, and
HSV-1 provide an indirect measure of cell-mediated
immune function. Findings from the psychoneuroimmu-
nology literature support a strong and consistent rela-
tionship between stress and increased antibody response
to herpesviruses [22]. Specifically, increases in herpes-
virus antibody titers have been linked to academic stress
in medical students and military cadets [23,24], caregiv-
ing for a family member with Alzheimer’s disease [25],
involvement in a poor quality marriage [22], traumatic
life events [26,27], as well as the psychological traits of
loneliness, defensiveness, and anxiety [28,29]. Specific to
CMV, antibodies have been shown to increase in
response academic stress in several student populations
[24,29], and the stress of spaceflight for astronauts[30].
Increased CMV antibody titers have been associated
with depression and anxiety in older adults[31].
Increased severity of parental psychiatric symptoms has
also been associated with an increase in the percentage
of CD4 and CD8 cells associated with immune control
over CMV in school-aged children[32]. Increased repli-
cation of CMV and antibody titer has been observed in
vitro and in vivo with administration of hydrocortisone
[33-35], as well from stress-related catecholamine
response[36].
Dried-Blood Spot Methods for Integrating Biomarkers
into Population-Based Research
The inclusion of biomarkers in social surveys has greatly
expanded in recent years[37]. Dried blood spots have
been incorporated into a number of major studies both
in the U.S. and internationally, including the Health and
Retirement Study (HRS), Los Angeles Family and Neigh-
borhood Study (L.A.FANS), National Longitudinal Study
of Adolescent Health (Add Health), National Social Life,
Health, and Aging Study (NSHAP), and the Mexican
Family Life Survey (MFLS). The addition of biomarkers
to such community and population-based surveys high-
lights efforts to understand the biological pathways
through which social and economic factors shape popu-
lation health. Historically, these surveys have relied pri-
marily on health data from self-reports or from vital
records. The addition of biomarkers has allowed investi-
gation of physiological processes that may be below the
threshold of perception to the individual but nonetheless
important predictors of future morbidity and mortality.
The development of minimally invasive methods for
sample collection also facilitates the inclusion of biomar-
kers into community-based research among a wider
range of diverse populations.
DBS samples offer several advantages for collection of
biomarkers, including access to physiological informa-
tion that would not otherwise be attainable in a non-
clinical setting and a relatively non-invasive sample
collection. Furthermore, unlike plasma or serum, DBS
samples do not need to be centrifuged, separated, or
immediately frozen following collection, providing con-
siderable flexibility for collection and transport. DBS
samples also remain stable in laboratory freezers for
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as new biomarkers of interest emerge[4].
Procedures for sample collection and processing are
relatively straightforward and have been described in
detail[4]. Briefly, the participant’s finger is cleaned with
isopropyl alcohol and then pricked with a sterile, dispo-
sable lancet similar to those used for blood glucose
m o n i t o r i n g .T h ef i r s td r o po fb l o o di sw i p e da w a yw i t h
gauze, and subsequent blood drops are applied to filter
paper. The samples are allowed to dry from four hours
to overnight, at which point they can be stacked and
stored in re-sealable plastic bags. The filter paper matrix
stabilizes most analytes in dried blood spots for
extended periods of time, but the rate of degradation
varies by analyte. Before analysis, the DBS sample must
first be brought into solution. A standard hole punch is
typically used to cut discs of whole blood of uniform
size. One or more discs are placed into an elution buffer
for a fixed amount of time, reconstituting the DBS as
hemolyzed liquid whole blood, which can then be used
in assays much as plasma or serum would be.
Among herpesviruses, dried-blood spot assays have
currently only been validated for Epstein-Barr virus
(EBV) antibodies[4,26]. While EBV has the advantage of
a higher seroprevalence at younger ages[38], CMV may
b eam o r eu s e f u lm e a s u r ef o rm i d d l e - a g e da n do l d e r
populations because of its links to aging and its seropre-
valence of over 80% among U.S adults 60 and over[39].
Compared to EBV, research has shown that CMV seems
to be dominant in causing the clonal expansions of dys-
regulated CD8 cells that are a crucial component of
immunosenescence[3]. Thus while antibodies to EBV
can provide an indirect marker of cell-mediated immune
function, antibody levels to CMV can provide both a
marker of stress-related changes in immune function as
well as a potentially clinically relevant marker of aging
and immune decline. A broadly available dried blood
spot assay for CMV antibody levels would facilitate
research on many fronts for understanding the psycho-
logical and social factors that accelerate aging.
Results
Assay protocol
A commercially available enzyme immunoassay kit for
measuring CMV IgG antibodies in serum or plasma
(Diamedix Corporation, No.720-320, Miami, FL) was
selected as the assay platform for the DBS protocol. The
day before an assay was to be performed, DBS samples
were removed from the freezer, and a small hole punch
was used to remove one 3.2-mm diameter disk of whole
blood. The disk was transferred with tweezers to a
labeled 12 × 75 mm glass tube, and 250 μL of diluent
buffer (supplied with the kit) were added. The sample
was covered and incubated overnight at 4°C.
The following day 100 uL of whole blood eluate were
transferred to microtiter plate wells in duplicate. For
calibration, the kit includes three levels of anti-CMV
antibody in stabilized human sera, and 100 uL of each
was added to the plate in duplicate. Wells were pre-
coated with purified CMV antigen, and anti-CMV IgG
antibody in the sample was bound to the plate during
incubation. Following a wash step, anti-human IgG con-
jugated with horseradish peroxidase was added to bind
to the antibody-antigen complex. Excess conjugate was
washed away and chromogenic substrate was added to
catalyze color development directly proportional to the
amount of anti-CMV IgG antibody in the sample.
Absorbance at 450 nm was obtained with a plate reader
spectrophotometer (BioTek ELx 808, Winooski, VT) for
the samples and for the calibrators.
Three calibrators were provided by the manufacturer
pre-diluted, with known concentrations of CMV anti-
body reported in ELISA units: 0, 10, and 160 EU/mL.
Absorbance values from the calibrators were used to
generate a best-fit linear standard curve, and CMV anti-
body concentrations for each sample were calculated
based on each sample’s absorbance value. It is important
to note that the calibrators are serum-based, while we
are using whole blood eluates as our sample. Therefore
we do not expect results from matched serum and DBS
samples to be identical, although we do expect a highly
correlated, linear relationship between the two sets of
results. The regression equation characterizing this rela-
tionship can be used to calculate serum-equivalent
values based on DBS results.
Assay validation
Assay precision, or intra-assay variation, was assessed
with 10 determinations of four control samples across
the assay range, all analyzed in a single run. Reliability,
or between-assay variation, was assessed by assaying
four control samples in duplicate across five different
days. For both intra- and inter-assay variation, the per-
cent coefficient of variation was calculated for each con-
trol sample (%CV = 100 × SD/mean). Assay linearity
was assessed by serially diluting three control samples
1:2, 1:4, and 1:8 in diluent buffer after elution. The ratio
of observed to expected values was calculated for each
dilution as a measure of assay accuracy across the assay
range.
The correlation between serum and DBS results was
evaluated using paired samples collected from 75 volun-
teers at the University of Michigan. The study was
approved by the Institutional Review Boards of the
University of Michigan and Hunter College, City
University of New York. A trained phlebotomist first
cleaned the participant’s finger with isopropyl alcohol
and then pricked with a sterile, disposable lancet. The
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sequent blood drops were applied to filter paper. The
samples were allowed to dry overnight and were subse-
quently stored at -20°C in re-sealable plastic bags with
desiccant. Venipuncture collection into 7.0 ml BD Vacu-
tainer
® glass serum tubes occurred immediately after
blood spot collection. Serum was removed, aliquotted,
and stored at -80°C. Samples were transported by auto-
mobile on dry ice from the University of Michigan to
the Laboratory for Human Biology at Northwestern
University for analysis. DBS samples obtained by finger-
prick were analyzed according to the protocol above.
Serum samples were analyzed according to procedures
specified by the kit for measuring CMV IgG antibodies
in serum or plasma (Diamedix Corporation, No.720-320,
Miami, FL).
Correlation and linear regression analyses were used to
evaluate the relationship between anti-CMV antibody
values derived from DBS and serum samples. In addition,
Bland-Altman plots were used to uncover evidence of bias
or inconsistent variability across the range of measure-
ment[40]. Seropositivity of serum samples was determined
according to test kit specifications, with < 8.0 EU/ml = ser-
onegative, 8.0-9.9 = equivocal, and ≥ 10 = seropositive.
The corresponding seropositivity cut-off for DBS samples
was determined based on the matched serum seropositiv-
ity results. One extremely high seropositive value (serum =
1806 EU/mL, DBS = 1040 EU/mL) was excluded from the
regression calculation for Figure 1.
Correlation between blood spot and plasma values
among positive serum samples was linear and high
(Pearson correlation R =. 9 6 )( F i g u r e1 ) .T h e r ew e r en o
equivocal samples among the sera, allowing definitive
seropositivity determination that was then compared to
DBS results. There was some overlap in positive and
negative DBS samples between EUs of 35 and 55, redu-
cing the sensitivity and specificity of the DBS seroposi-
tivity cut-off relative to the serum assay. Table 1 shows
DBS sensitivity and specificity values at different DBS
cut-off values. For the purposes of measuring continu-
ous CMV antibody level in middle-aged and older popu-
lations where the majority of individuals are already
seropositive, precise ascertainment of dichotomous sero-
positivity is less crucial and investigators may choose a
lower, more lenient cut-off to reduce the number of
false-negative individuals. For investigators more con-
cerned with seropositivity as an outcome itself, a higher,
more conservative cut-off can be used to help reduce
the number of false-positives.
Precision and Reliability
As seen in Table 2, precision and reliability were excel-
lent in the middle control ranges. More variability was
seen in the negative sample, as well as in the highest
control sample, with 11% intra-assay variability and 10%
inter-assay variability, respectively.
Linearity
To evaluate linearity, three high samples were serially
diluted: 1:1; 1:2; 1:4; and 1:8. Mean recovery (100 ×
observed/expected) was 104.8%, and ranged from 98%
to 112%, indicating a high degree of linearity across the
assay range.
Discussion
Results of our assay validation demonstrate that deter-
mination of CMV antibody titers using dried blood
s p o t si sf e a s i b l ea n dp r o v i d e sas e n s i t i v e ,p r e c i s e ,a n d
reliable measure. The use of DBS methodology in popu-
lation-level research has many advantages compared to
venipuncture including low cost and ease of sample col-
lection, storage, and transportation, facilitating collection
in settings outside of the clinic or laboratory. Respon-
dent burden is also minimized, increasing the potential
for more frequent collection. These advantages broaden
the possibility for inclusion of such markers in large,
representative samples to overcome the limitations of
smaller clinical studies.
Figure 1 Correlation between Matched Dried Blood Spot and
Serum Samples, CMV IgG.
Table 1 DBS Seropositivity Sensitivity and Specificity
Cut-Off (EU/mL) Sensitivity Specificity
35 100.0% 80.9%
46 92.9% 93.6%
48.5 85.7% 95.7%
51.5 82.1% 97.9%
56 82.1% 100.0%
Sensitvity = % of positive serum samples testing positive with DBS.
Specificity = % of negative serum samples testing negative with DBS.
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stress, the inclusion of CMV antibody levels in DBS
assays from population surveys can be an important tool
for elucidating how psychological and social factors
translate into health outcomes over the life span. Prior
to this study, of the various herpesviruses that have
been linked to stress. a validated DBS assay was avail-
able only for EBV[26]. While EBV has been used effec-
tively as marker of cell-mediated immunity related to
s t r e s s ,C M Vm a yp r o v et ob eam o r ev a l u a b l em a r k e r
for looking at both stress and immune system aging.
Research has found that EBV and CMV infections
induce quantitatively and qualitatively different CD8 T-
cell responses in advanced aging, with EBV chronic
infection kept under control by a limited and stable
number of circulating CD8+ CD28+ T cells compared
to CMV which seems to dominate clonal expansion[41].
Many of the biological changes that occur in response
to chronic stress appear to parallel those observed in
aging. Stress and aging are further linked through life
changes such as bereavement and caregiving. While
stress is known to elicit a variety of biological responses
that can contribute to the development of disease, the
specific mechanisms linking stressors to aging are not
well understood. Periodic subclinical reactivation of
C M Vd u et os t r e s sm a yc o n t r i b u t et oa ni n c r e a s ei n
CMV-specific T cells over time, accelerating immunose-
nescence[7].
T h er o l eo fs t r e s si ne x p l a i n ing socioeconomic differ-
ences in health has been explored using neuroendo-
crine markers of stress such as cortisol, but the nature
of cortisol measurement has contributed to the incon-
sistent results of these studies[42]. Antibody levels to
CMV provide a promising alternative to neuroendo-
crine measures for understanding the dynamics of
social factors, stress, and health. At the population
level, CMV seroprevalence is higher in children and
adults with lower socioeconomic status (SES) and non-
white race/ethnicity in the U.S.[43], and socioeconomic
differences in antibody response to CMV among sero-
positive individuals have also been identified[44].
I n c r e a s e di m m u n ev i g i l a n c eo v e rC M Vm a yt a k eat o l l
on these disadvantaged groups via earlier onset
of immunosenescence, as well as increased levels
of inflammation and inflammatory-related chronic dis-
eases. The addition of CMV antibodies to population-
based studies of aging would allow exploration of novel
hypotheses linking stress, immune function, and health
outcomes at older ages.
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